Severe hypercalcaemia is usually due to either neoplastic disease or primary hyperparathyroidism. Rarer causes do exist, and exceptionally these may occur concomitantly. We describe the case of a 45-year-old man who presented in a debilitated state with severe hypercalcaemia (total serum calcium 3 ¢ 56 mmol/L, albumin 35 g/L) and suppressed serum parathyroid hormone concentration. It was initially suspected that he had neoplastic disease, but routine thyroid function tests demonstrated evidence of thyrotoxicosis [thyroid-stimulating hormone 50 ¢ 05 mU/L (0 ¢ 15-3 ¢ 5); free thyroxine 75 pmol/L (8-27); total tri-iodothyronine 7 ¢ 0 nmol/L (1 ¢ 0-2 ¢ 6)], which was probably secondary to a silent or subacute thyroiditis. After extensive investigation, it was established that the patient also had isolated adrenocorticotrophic hormone de ciency, presumably secondary to lymphocytic hypophysitis. Glucocorticoid therapy resulted in a dramatic improvement in the patient's clinical state and 1 year later he remained euthyroid and normocalcaemic.
Introduction
Severe hypercalcaemia rarely poses a major diagnostic challenge to endocrinologists and general physicians, because the majority of cases are due either to neoplastic disease or to primary hyperparathyroidism. The serum parathyroid hormone concentration (which is usually low in neoplastic disease) will help distinguish between these two main causes if the diagnosis of neoplasia is not already established. Rare causes of hypercalcaemia do exist, however, and occasionally these can occur simultaneously, resulting in severe hypercalcaemia.We report the case of a 45-year-old man who presented in a debilitated state with severe hypercalcaemia and in whom we had signi¢cant di¤culty in establishing the underlying aetiology.
Case history
A 45-year-old man was admitted with a 6-week history of anorexia, diarrhoea, night sweats and myalgia. He had lost approximately 10 kg in weight and was intermittently confused. He had no previous medical history of note and was not taking regular medication, but was known to drink alcohol to excess.
On examination, he was cachectic and clearly unwell. His Abbreviated Mental Test score was 7/10; he was clinically dehydrated and had a pulse rate of 130/min and a blood pressure of 99/61 mmHg. Clinical examination was otherwise unremarkable.
Initial blood test results revealed severe hypercalcaemia and biochemical evidence of dehydration: urea 10¢8 mmol/ L; creatinine 66 mmol/L; sodium 133 mmol/L; potassium 5¢5 mmol/ L; total calcium 3 ¢ 56 mmol/L; phosphate 1 ¢ 51mmol/L; albumin 35 g/L; glucose 5¢8 mmol/ L; protein electrophoresis normal; parathyroid hormone 58 ng/L (normal range 10-65); 25-hydroxyvitamin D 56 nmol/ L (15-100). Ionized calcium was not measured. A chest radiograph was normal. The patient was treated with intravenous crystalloid £uids and one intravenous infusion of pamidronate (60 mg). His serum calcium normalized within 48 h, but thyroid function tests revealed a thyrotoxic picture: thyroid-stimulating hormone (TSH) 50 ¢05 mU/L (0¢15-3¢5); free thyroxine 75 pmol/L (8-27); total tri-iodothyronine 7¢0 nmol/ L (1¢0 -2¢6). Antibodies to thyroid peroxidase and thyrotrophin receptor were undetectable. Anti-thyroid therapy with carbimazole was commenced, but treatment with propranolol resulted in hypotension and was subsequently withdrawn. Over the next week he was Case Report intermittently confused and he remained persistently tachycardic and lethargic. A computed tomographic scan of the brain, an abdominal ultrasound scan and a radionuclide bone scan were normal.
In view of the initial presentation with mild hyponatraemia and hyperkalaemia, a short Synacthen test was performed: the basal cortisol concentration was 550 nmol/ L and the 30-min (post 250 mg of intramuscular Synacthen) cortisol concentration was 64 nmol/ L, con¢rming profound glucocorticoid de¢ciency. The serum adrenocorticotrophic hormone (ACTH) concentration was 510 ng/L and remained undetectable following intravenous administration of 100 mg of corticotrophin-releasing factor. Erect and supine renin concentrations were normal and antiadrenal antibodies were negative. Serum prolactin, testosterone, insulin-like growth factor-1 and gonadotrophin concentrations and a magnetic resonance imaging (MRI) scan of the pituitary and hypothalamus were normal.
Hydrocortisone was commenced and the patient's clinical condition rapidly improved. Within 24 h he was well enough for discharge home. At clinic review 4 weeks later, when taking 20 mg carbimazole three times a day, he was biochemically hypothyroid (TSH 15 ¢ 20 mU/L; free thyroxine 6 pmol/L). The carbimazole dose was reduced to 20 mg daily and discontinued 1 month later when the TSH was 5¢00 mU/L and free thyroxine 12 nmol/ L. Thyroid scintigraphy at that time showed symmetrical uptake of 99 technetium pertechnate. More than 12 months later, the patient was well on 15 mg of hydrocortisone daily and remained euthyroid and normocalcaemic. A repeat MRI scan of the pituitary and hypothalamus was unremarkable.
Discussion
The debilitated state of the patient and the suppressed serum parathyroid hormone concentration initially suggested that the severe hypercalcaemia was secondary to an underlying malignancy. However, thyrotoxicosis was diagnosed on the initial blood screen, on the basis of a suppressed TSH level and elevated free thyroxine concentration. The total triiodothyronine concentration was also signi¢cantly raised, strongly suggesting that the thyroid function test abnormalities were not due to`non-thyroidal illness'. 1 Thyroid scintigraphy was not performed when the patient was thyrotoxic, but showed symmetrical uptake when his serum TSH was elevated. Taken together with the rapid development of hypothyroidism on carbimazole, the maintenance of a euthyroid state after discontinuation of a short course of anti-thyroid therapy and the absence of anti-thyroid antibodies, it would seem most probable that the thyrotoxicosis was secondary to an episode of silent or subacute thyroiditis.
Because of our ongoing concern that an underlying neoplastic process was contributing to the hypercalcaemia, the co-existence of glucocorticoid de¢ciency (secondary to isolated ACTH de¢ciency) was not established for over a week. Isolated ACTH de¢ciency is rare and is not usually associated with structural pituitary disease. There are, however, reports of isolated ACTH de¢ciency occurring secondary to lymphocytic hypophysitis, where selective damage of pituitary corticotropes by an autoimmune process has presumably taken place. 2^4 There was no histological con¢rmation of such a process in the present case.
Hypercalcaemia is a recognized complication of thyrotoxicosis, because of increased thyroid hormone-mediated osteoclastic bone resorption, 5, 6 but it is invariably mild. 7, 8 In one series of 437 patients with thyrotoxicosis, the serum calcium concentration was greater than 2¢65 mmol/ L in 8¢5% of patients, but there were no instances of symptomatic hypercalcaemia. 8 Indeed, the maximum serum calcium concentration was 2¢80 mmol/ L and that was observed in a patient who had coincidental primary hyperparathyroidism. 8 As with thyrotoxicosis, hypercalcaemia is an established complication of primary adrenocortical failure. 9^11 The hypercalcaemia may, in part, be due to volume depletion and reduced glomerular ¢ltration rate, but correction of the hypovolaemia does not necessarily normalize the serum calcium concentration. 9, 10 An increase in calcium e¥ux from bone also seems to occur in hypoadrenalism and contributes to the hypercalcaemia. 11 It has been speculated that the calcium mobilization from bone in hypoadrenalism is mediated by thyroid hormones^that at physiological concentrations, glucocorticoids limit thyroid hormone-mediated bone turnover. 12 Evidence in support of this hypothesis comes from a variety of sources. In vitro, thyroid hormone-stimulated bone resorption is inhibited by cortisol, 13 while adrenalectomized dogs only develop hypercalcaemia in the presence of a thyroid gland. 14 In humans, severe hypercalcaemia may occur in patients with co-existing Addison's disease and Graves' thyrotoxicosis 15, 16 and there is also one report of lifethreatening hypercalcaemia developing in a 35-year-old woman with Addison's disease after she was commenced on thyroxine for primary hypothyroidism. 17 It is not known how glucocorticoids modulate the actions of thyroid hormones on bone, but possible explanations are that glucocorticoids downregulate thyroid hormone receptors or suppress local bone prostaglandin production. 18 Hypercalcaemia secondary to the combination of isolated ACTH de¢ciency and thyrotoxicosis (secondary to thyroiditis) is exceptionally rare and has only been previously described in four cases. 2, 3, 12, 19 All were young women in the post-partum period; in three of the cases the hypercalcaemia was severe (43¢1 mmol/ L) and in one tragic case the diagnosis was delayed and the patient sustained a cardiorespiratory arrest and subsequently died. 2 In one further case, severe hypercalcaemia occurred in the puerperium of an 18-year-old woman with post-partum thyroiditis and presumed lymphocytic hypophysitis, although in this case the patient was ACTH-, prolactin-and growth-hormone-de¢cient. 20 The present case appears to be unique in that the combination of severe hypercalcaemia, isolated ACTH de¢ciency and thyroiditis occurred in a man. Although there is no way of con¢rming this, our presumption is that he had long-standing ACTH de¢ciency, but only became unwell when he developed a thyroiditis that precipitated severe hypercalcaemia in the context of the glucocorticoid de¢ciency. The long-term maintenance of a euthyroid and normocalcaemic state on glucocorticoid replacement therapy alone would tend to support this hypothesis. The present case and the ¢ve others in post-partum women, further reinforce the observation that volume depletion is not a major contributor to the hypercalcaemia in primary adrenocortical failure, as secondary hypoadrenalism is not associated with mineralocorticoid de¢ciency. It must be presumed that severe hypercalcaemia is not more frequently encountered in patients with ACTH de¢ciency as concomitant thyrotropin de¢ciency often occurs.
In summary, the present case highlights that rarer causes of hypercalcaemia exist and that assessment of thyroid function and adrenocortical reserve should be considered in patients with hypercalcaemia associated with a low serum parathyroid hormone concentration. Clinicians should be alert to the possibility that more than one precipitant of hypercalcaemia may occur simultaneously. The combination of severe hypercalcaemia secondary to isolated ACTH de¢ciency and thyroiditis has not previously been described in a man and provides an intriguing insight into the relationship between thyroid hormones and glucocorticoids in bone.
